Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinical trial NCT04209621 · TERMINATED

Trial details

NCT number: NCT04209621
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Small Lymphocytic Leukemia (SLL)Chronic Lymphocytic Leukemia (CLL)

Start date: 2020-07-31
Primary completion: 2021-01-22
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.